Novo Nordisk
2025.07.26
00:07
Eli Lilly (LLY.N) rose 0.14% and Novo Nordisk (NVO.N) rose 0.88% as bipartisan U.S. lawmakers put pressure on the U.S. Food and Drug Administration to crack down on compounded and counterfeit GLP-1 drugs.
2025.07.18
19:21
Novo Nordisk's semaglutide injection for chronic kidney disease approved in China
On July 18, Novo Nordisk announced that the National Medical Products Administration (NMPA) recently officially approved the new chronic kidney disease (CKD) indication for Novotec (semaglutide injection), making it the first and only GLP-1 receptor agonist (GLP-1RA) in China approved to reduce the risk of continued decline in eGFR, end-stage renal disease and cardiovascular death in adult patients with type 2 diabetes and chronic kidney disease.
2025.07.10
07:09
Nearly 10 billion US dollars flow into AI pharmaceutical new drug research and development, pressing the acceleration key
According to the Securities Times, AI pharmaceuticals have recently attracted market attention due to frequent project cooperation and investment and financing events. The reporter learned from the industry that as AI accelerates its penetration into the pharmaceutical industry, the research and development of innovative drugs has ushered in a milestone progress, and the results of AI pharmaceuticals have blossomed in many places. At the same time, AI pharmaceuticals are facing commercial difficulties, and it will take time to solve them. Recently, large orders in the field of AI pharmaceuticals have frequently appeared. On June 11, Novo Nordisk reached a US$812 million cooperation with AI pharmaceutical company Deep Apple Therapeutics; on June 12, Eli Lilly and Juvena Therapeutics (an American AI pharmaceutical company) signed an agreement of more than US$650 million; on June 13, AstraZeneca (AZ) and Shijiazhuang Pharmaceutical Group reached a cooperation of up to US$5.3 billion to use Shijiazhuang Pharmaceutical Group's AI drug discovery platform to develop small molecule drug candidates. On June 23, Jingtai Holdings, a leading domestic AI pharmaceutical company, signed a multi-billion dollar pipeline licensing cooperation letter of intent with DoveTree LLC (a company founded by Gregory Verdine, a legendary entrepreneur and investor in the US pharmaceutical industry); on the same day, AI pharmaceutical company Formation Bio announced that its subsidiary had licensed the oral dual JAK/SYK inhibitor gusacitinib to Sanofi, with the maximum cooperation amount reaching 545 million euros. In less than a month, nearly 10 billion US dollars flowed into the AI pharmaceutical industry, causing a stir in the industry.
2025.07.08
21:15
Novo Nordisk (NVO.N): New doses of its weight loss drug Wegovy have been submitted to the European Medicines Agency for approval. One-third of trial participants achieved a weight loss of 25% or more.
2025.06.26
22:49
The first domestically produced GLP-1 weight loss innovative drug is about to be approved, and the unofficial price has been revealed
Reporters learned from multiple sources that the weight loss indication of Masdu peptide injection, the first domestically produced GLP-1 weight loss innovative drug developed by Innovent Biologics, is expected to be approved as early as this week. As of the close of June 26, Innovent Biologics' stock price fell by about 5%. Innovent Biologics previously publicly stated that both weight loss and glucose-lowering indications of Masdu peptide are expected to be approved this year. Masdu peptide is the world's first GCG/GLP-1 dual receptor agonist weight loss drug. After approval, it is expected to break the current global weight loss drug competition dominated by multinational giants Novo Nordisk and Eli Lilly, and is expected to improve the accessibility of GLP-1 weight loss drugs.
2025.06.23
21:33
Novo Nordisk (NVO.N) fell more than 6% after the company announced the termination of its cooperation with HIMS & HERS. The latter fell 27%, the biggest single-day drop since February.
21:31
The three major U.S. stock indexes opened slightly lower
The three major U.S. stock indexes opened slightly lower, with the Dow Jones Industrial Average down 0.11%, the Nasdaq down 0.12%, and the S&P 500 down 0.03%. Novo Nordisk fell more than 6% after the company announced the termination of its cooperation with HIMS & HERS. AMD fell more than 4% after the company announced plans to issue $2 billion in convertible senior notes.
19:51
Novo Nordisk's US stock fell nearly 6% before the market opened
Novo Nordisk's pre-market losses in the U.S. widened, now down 5.84%.
19:39
HIMS & HERS fell 7.5% pre-market after Novo Nordisk announced the termination of its cooperation with the company
HIMS & HERS fell 7.5% in premarket trading after Novo Nordisk announced it was terminating its partnership with the company.
18:03
Yifan Pharmaceuticals: Human growth hormone injection approved for drug clinical trials
Yifan Pharmaceuticals announced that its wholly-owned subsidiary Yifan Pharmaceuticals (Shanghai) Co., Ltd. recently received the "Notice of Approval for Drug Clinical Trial" approved and issued by the National Medical Products Administration. The drug name is human growth hormone injection, the English name is Human Somatropin Injection, the dosage form is injection, and the registration classification is Class 3.3 of therapeutic biological products. According to the "Drug Administration Law of the People's Republic of China" and relevant regulations, after review, it is agreed to conduct clinical trials in accordance with the requirements of biosimilars. Human growth hormone injection is a biosimilar developed by the company to Novo Nordisk's recombinant human growth hormone injection (trade name: Noze), which has the same amino acid sequence as natural human growth hormone and is currently the mainstream treatment for growth hormone deficiency.
16:13
Novo Nordisk fell nearly 4% before the market opened. The clinical trial data of the new weight loss drug was lower than expected.
Novo Nordisk fell nearly 4% in pre-market trading to $70.87. On the news front, Novo Nordisk disclosed the complete data of two Phase III clinical trials of its new weight loss drug CagriSema, showing that the drug performed positively in terms of weight loss and improvement of metabolic indicators, but the incidence of gastrointestinal side effects was higher than that of the placebo group. This result is basically consistent with the previously announced interim data, but it failed to fully meet the expectations of the capital market. Novo Nordisk previously announced the details of a 68-week clinical study at the American Diabetes Association Annual Meeting held in Chicago. Overweight or obese non-diabetic patients treated with CagriSema lost an average of about 23% of their weight, and patients with type 2 diabetes and overweight lost 15.8%.
2025.06.21
11:58
Novo Nordisk announces latest study results of semaglutide: Higher doses of Wegovy can reduce the average weight of obese patients by 21%
On June 21, Novo Nordisk announced the results of the Phase 3b STEPUP trial for non-diabetic obese patients at the American Diabetes Association (ADA) Scientific Conference in Chicago, according to the Novo Nordisk website. The data showed that during the 72-week treatment period, a higher dose of Wegovy (semaglutide 7.2 mg) could reduce the average weight of obese patients by 21% compared with placebo, with one-third of the subjects losing 25% or more. The safety and tolerability of the higher dose of Wegovy (7.2 mg) were consistent with the 2.4 mg dose.
2025.06.13
16:07
Market news: Novo Nordisk (NVO.N) surpasses SAP SE (SAP.N) to become Europe's most valuable company.
2025.06.11
18:55
Nvidia collaborates with Novo Nordisk and the Danish Center for Artificial Intelligence Innovation (DCAI) to advance drug discovery
Nvidia is collaborating with Novo Nordisk and the Danish Center for Artificial Intelligence Innovation (DCAI) to advance drug discovery.
2025.06.10
16:02
Novo Nordisk's US stock rose more than 2% before the market opened
Novo Nordisk's U.S. shares rose more than 2% in pre-market trading after media reports that Parvus Asset Management was increasing its stake in Novo Nordisk.
Load More
Email Subscription
Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.
Weekly Highlights
Beijing, the "capital of open source", accelerates the construction of domestic open source big models and achieves another breakthrough

2025-07-25

Academician of the Singapore Academy of Engineering: Building a sound development mechanism for China-ASEAN artificial intelligence industry

2025-07-19

PICO and Blender Foundation enter into partnership

2025-07-23

The world's first active safety AI battery cell goes into mass production

2025-07-27

Jida Zhengyuan was selected into Huawei Digital Government High-Quality Service Industry Alliance

2025-07-22

ASIA TECH WIRE

Grasp technology trends

Download